JP2017534262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534262A5 JP2017534262A5 JP2017515139A JP2017515139A JP2017534262A5 JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5 JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017515139 A JP2017515139 A JP 2017515139A JP 2017534262 A5 JP2017534262 A5 JP 2017534262A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- nucleotide sequence
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020017583A JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2021169396A JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053068P | 2014-09-19 | 2014-09-19 | |
| US62/053,068 | 2014-09-19 | ||
| PCT/US2015/051089 WO2016044811A1 (en) | 2014-09-19 | 2015-09-18 | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017583A Division JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534262A JP2017534262A (ja) | 2017-11-24 |
| JP2017534262A5 true JP2017534262A5 (enExample) | 2018-10-25 |
| JP6657195B2 JP6657195B2 (ja) | 2020-03-04 |
Family
ID=55533940
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515139A Active JP6657195B2 (ja) | 2014-09-19 | 2015-09-18 | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2021169396A Active JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2021169396A Active JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9914909B2 (enExample) |
| EP (4) | EP3587446A1 (enExample) |
| JP (7) | JP6657195B2 (enExample) |
| KR (3) | KR102683584B1 (enExample) |
| CN (4) | CN113789336B (enExample) |
| AU (4) | AU2015317351B2 (enExample) |
| BR (3) | BR122024000360A2 (enExample) |
| CA (2) | CA2961654A1 (enExample) |
| DK (1) | DK3200591T3 (enExample) |
| ES (2) | ES2738705T3 (enExample) |
| IL (6) | IL308324A (enExample) |
| MX (4) | MX387135B (enExample) |
| RU (2) | RU2749922C2 (enExample) |
| WO (2) | WO2016044811A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738696B2 (en) | 2012-08-09 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| CN113307880B (zh) | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| IL308324A (en) | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
| EA202090931A3 (ru) | 2015-05-18 | 2020-10-30 | Тср2 Терапьютикс Инк. | Композиции и способы перепрограммирования tcr с помощью гибридных белков |
| US12115189B2 (en) | 2015-07-21 | 2024-10-15 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| RU2724738C2 (ru) * | 2015-08-05 | 2020-06-25 | СеллабМЕД ИНК. | Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор |
| IL261941B2 (en) | 2016-04-01 | 2023-11-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| US20190183931A1 (en) * | 2016-04-01 | 2019-06-20 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| SI3436030T1 (sl) | 2016-04-01 | 2023-01-31 | Kite Pharma, Inc. | Himerni receptorji in načini njihove uporabe |
| TWI761831B (zh) * | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| CA3026778A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CA3025667A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CN110177558B (zh) * | 2016-09-16 | 2025-02-28 | 贝勒医学院 | 用于病毒特异性t细胞的活化和扩增的平台 |
| CN112280796A (zh) | 2016-10-07 | 2021-01-29 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CN108395481B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| EP3604344A4 (en) * | 2017-03-27 | 2021-01-06 | Noile-Immune Biotech, Inc. | CHEMICAL ANTIGENIC RECEPTOR |
| WO2018191748A1 (en) | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| JP7391831B2 (ja) * | 2017-08-11 | 2023-12-05 | シティ・オブ・ホープ | Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用 |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| AU2018362014A1 (en) * | 2017-11-03 | 2020-05-28 | Sorrento Therapeutics, Inc. | CD38-directed chimeric antigen receptor constructs |
| WO2019094498A1 (en) * | 2017-11-07 | 2019-05-16 | City Of Hope | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| EP3749695A4 (en) * | 2018-02-06 | 2021-12-29 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| EA202091984A1 (ru) * | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| CA3093810A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
| AU2019249215A1 (en) | 2018-04-06 | 2020-10-22 | The Regents Of The University Of California | Methods of treating EGFRvIII expressing glioblastomas |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| KR20210013691A (ko) * | 2018-05-21 | 2021-02-05 | 바이오셉터 (유케이) 리미티드 | 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도 |
| CA3102097A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| CN113260369B (zh) * | 2018-08-10 | 2024-08-23 | 优特力克斯有限公司 | 癌抗原特异性细胞毒性t细胞 |
| SG11202104287RA (en) * | 2018-11-06 | 2021-05-28 | Univ Washington | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same |
| WO2020191336A1 (en) | 2019-03-21 | 2020-09-24 | Yamaguchi, Yukiko | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| US20220145252A1 (en) | 2019-03-29 | 2022-05-12 | City Of Hope | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| JP2022533247A (ja) * | 2019-05-24 | 2022-07-21 | シティ・オブ・ホープ | Ｃｃｒ４陽性悪性腫瘍治療用ｃｃｒ４標的化キメラ抗原受容体修飾ｔ細胞 |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| KR20220038397A (ko) * | 2019-07-24 | 2022-03-28 | 리제너론 파아마슈티컬스, 인크. | Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도 |
| EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
| WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| WO2021154543A2 (en) | 2020-01-31 | 2021-08-05 | City Of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES |
| WO2021183755A1 (en) * | 2020-03-11 | 2021-09-16 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| EP4118106A1 (en) * | 2020-03-12 | 2023-01-18 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
| EP4143300A1 (en) | 2020-04-28 | 2023-03-08 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3184784A1 (en) * | 2020-05-27 | 2021-12-02 | The Medical College Of Wisconsin, Inc. | Improved lentiviral vector transfer plasmid and methods of use |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| MX2023001771A (es) * | 2020-08-11 | 2023-04-25 | Yeda Res & Dev | Celulas car-t de veto. |
| IL301233A (en) * | 2020-09-10 | 2023-05-01 | Mustang Bio Inc | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
| US20240009239A1 (en) * | 2020-11-04 | 2024-01-11 | Fred Hutchinson Cancer Center | Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy |
| WO2022109498A1 (en) | 2020-11-23 | 2022-05-27 | City Of Hope | Engineered t cells for expression of chimeric anitgen receptors |
| WO2022120334A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| WO2022198027A1 (en) * | 2021-03-18 | 2022-09-22 | The Wistar Institute Of Anatomy And Biology | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Rα2 AND METHODS OF USE IN CANCER THERAPEUTICS |
| CN117242090A (zh) | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| US20230190799A1 (en) * | 2021-07-21 | 2023-06-22 | City Of Hope | Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| WO2023130462A1 (zh) * | 2022-01-10 | 2023-07-13 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| EP4588939A1 (en) | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| RU2167676C2 (ru) * | 1995-02-24 | 2001-05-27 | Дзе Дженерал Хоспитал Корпорейшн | Перенаправление клеточного иммунитета посредством химерных рецепторов |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| ATE292473T1 (de) | 1998-07-30 | 2005-04-15 | Us Gov Health & Human Serv | Thymosin beta 4 stimuliert wundheilung |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| EP1263785A2 (en) * | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US11278594B2 (en) * | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2002256390B2 (en) | 2001-04-30 | 2007-08-30 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| ATE373904T1 (de) | 2003-07-24 | 2007-10-15 | Matsushita Electric Industrial Co Ltd | Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7754441B2 (en) * | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| DE102004043271A1 (de) * | 2004-09-07 | 2006-03-09 | Linde Ag | Verfahren zur Synthese von Zirkoniumcarboxylaten |
| US20060269973A1 (en) * | 2004-11-24 | 2006-11-30 | Cassian Yee | Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens |
| CN101346463B (zh) * | 2005-12-21 | 2012-06-13 | 江苏太瑞生诺生物医药科技有限公司 | 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法 |
| US20080293070A1 (en) | 2005-12-21 | 2008-11-27 | Rafick-Pierre Sekaly | Markers for Memory T Cells and Uses Thereof |
| PL2126054T3 (pl) | 2007-01-31 | 2017-01-31 | Yeda Research And Development Company Limited | Przekierowane, genetycznie modyfikowane regulatorowe komórki T i ich zastosowanie w hamowaniu choroby autoimmunologicznej i zapalnej |
| CN101842387B (zh) * | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| ES2553421T3 (es) * | 2008-08-26 | 2015-12-09 | City Of Hope | Método y composiciones para el funcionamiento potenciado del efector antitumoral de células T |
| US20130011401A1 (en) * | 2009-12-22 | 2013-01-10 | Novartis Ag | Soluble proteins for use as therapeutics |
| GB2481983A (en) * | 2010-07-12 | 2012-01-18 | Hart Fenton & Co Ltd | A ship including a gas tank room |
| US20130164272A1 (en) | 2010-08-18 | 2013-06-27 | Udai S. Kammula | Methods of identifying central memory t cells and obtaining antigen-specific t cell populations |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG193591A1 (en) * | 2011-03-23 | 2013-10-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| BR112013024574B1 (pt) * | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR102264290B1 (ko) * | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| IL308324A (en) | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
-
2015
- 2015-09-18 IL IL308324A patent/IL308324A/en unknown
- 2015-09-18 CA CA2961654A patent/CA2961654A1/en active Pending
- 2015-09-18 JP JP2017515139A patent/JP6657195B2/ja active Active
- 2015-09-18 RU RU2017111298A patent/RU2749922C2/ru active
- 2015-09-18 BR BR122024000360-0A patent/BR122024000360A2/pt not_active Application Discontinuation
- 2015-09-18 ES ES15775539T patent/ES2738705T3/es active Active
- 2015-09-18 KR KR1020177010183A patent/KR102683584B1/ko active Active
- 2015-09-18 EP EP19175730.1A patent/EP3587446A1/en not_active Withdrawn
- 2015-09-18 EP EP15775539.8A patent/EP3194433B1/en active Active
- 2015-09-18 BR BR112017005631-3A patent/BR112017005631A2/pt not_active IP Right Cessation
- 2015-09-18 IL IL292650A patent/IL292650B2/en unknown
- 2015-09-18 CN CN202110969587.7A patent/CN113789336B/zh active Active
- 2015-09-18 AU AU2015317351A patent/AU2015317351B2/en active Active
- 2015-09-18 WO PCT/US2015/051089 patent/WO2016044811A1/en not_active Ceased
- 2015-09-18 MX MX2017003596A patent/MX387135B/es unknown
- 2015-09-18 CN CN201580061133.2A patent/CN107002084B/zh active Active
- 2015-09-21 EP EP21166086.5A patent/EP3916084A1/en active Pending
- 2015-09-21 CA CA2961676A patent/CA2961676A1/en active Pending
- 2015-09-21 RU RU2017111300A patent/RU2763523C2/ru active
- 2015-09-21 EP EP15842405.1A patent/EP3200591B2/en active Active
- 2015-09-21 CN CN201580062281.6A patent/CN107404881B/zh active Active
- 2015-09-21 ES ES15842405T patent/ES2876235T5/es active Active
- 2015-09-21 CN CN202110690954.XA patent/CN113637640A/zh active Pending
- 2015-09-21 MX MX2017003557A patent/MX383042B/es unknown
- 2015-09-21 JP JP2017515138A patent/JP6711819B2/ja active Active
- 2015-09-21 DK DK15842405.1T patent/DK3200591T3/da active
- 2015-09-21 WO PCT/US2015/051280 patent/WO2016044853A1/en not_active Ceased
- 2015-09-21 IL IL251188A patent/IL251188B/en unknown
- 2015-09-21 KR KR1020237041649A patent/KR20230169455A/ko not_active Ceased
- 2015-09-21 BR BR112017005630-5A patent/BR112017005630B1/pt not_active IP Right Cessation
- 2015-09-21 KR KR1020177010184A patent/KR102610715B1/ko active Active
-
2016
- 2016-05-27 US US15/167,869 patent/US9914909B2/en active Active
-
2017
- 2017-03-15 IL IL251196A patent/IL251196B/en active IP Right Grant
- 2017-03-16 MX MX2021006400A patent/MX2021006400A/es unknown
- 2017-03-17 MX MX2021012720A patent/MX2021012720A/es unknown
-
2018
- 2018-03-12 US US15/918,901 patent/US10676717B2/en active Active
-
2020
- 2020-02-05 JP JP2020017583A patent/JP6986190B2/ja active Active
- 2020-05-06 US US16/867,803 patent/US20200318069A1/en active Pending
- 2020-05-28 JP JP2020093109A patent/JP7216045B2/ja active Active
- 2020-06-03 AU AU2020203651A patent/AU2020203651A1/en not_active Abandoned
-
2021
- 2021-02-02 IL IL280576A patent/IL280576B/en unknown
- 2021-10-15 JP JP2021169396A patent/JP7171871B2/ja active Active
- 2021-11-30 AU AU2021277651A patent/AU2021277651A1/en not_active Abandoned
-
2022
- 2022-05-08 IL IL292828A patent/IL292828A/en unknown
- 2022-11-02 JP JP2022176776A patent/JP2023014100A/ja active Pending
-
2023
- 2023-01-19 JP JP2023006410A patent/JP2023052506A/ja not_active Ceased
-
2024
- 2024-02-28 AU AU2024201326A patent/AU2024201326A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534262A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| JP2014012688A5 (enExample) | ||
| EP3821011A4 (en) | TRANSPOSOME-ACTIVATED DNA/RNA SEQUENCING (TED RNA-SEQ) | |
| JP2016525888A5 (enExample) | ||
| JP2010088434A5 (enExample) | ||
| JP2017048194A5 (enExample) | ||
| JP2011155981A5 (enExample) | ||
| CA3062698A1 (en) | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof | |
| WO2018004308A3 (ko) | 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법 | |
| MX395611B (es) | Receptores de celulas t. | |
| JP2016185981A5 (enExample) | ||
| JP2016104015A5 (enExample) | ||
| MX372992B (es) | Vector de virus adeno-asociado. | |
| JP2010227108A5 (enExample) | ||
| JP2014518898A5 (enExample) | ||
| WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
| EA038402B9 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
| CL2013001124A1 (es) | Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo. | |
| JP2017501211A5 (enExample) | ||
| EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
| EA201990884A1 (ru) | АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018531624A5 (enExample) | ||
| JP2015038108A5 (enExample) | ||
| JP2013539454A5 (enExample) |